|
CANCERS BRONCHIQUES A PETITES CELLULES
CHIMIOTHERAPIE ALTERNANTE ET SEQUENTIELLE |
|
|
Référence |
chimiothérapie |
bras |
stade |
nb pts |
RO % |
SM |
p |
|
Chak, 1982 |
A :PCZ-VCR-CPA-CCNU B :VP16-ADR-MTX |
A |
tous |
85 |
NS |
||
|
B~A |
76 |
||||||
|
Osterlind, 1983 |
A :BCNU-CPA-VCR-MTX B :ADR-VP16 |
A |
ME |
76 |
68 |
36s |
NS |
|
A~B |
70 |
72 |
38s |
||||
|
Daniels, 1984 |
A : CPA-VCR-PCZ-CCNU B : VP16-ADR-MTX |
A |
tous |
84 |
53 |
NS |
|
|
Ax3~B |
78 |
63 |
|||||
|
Livingston, 1984 |
A :VCR-MTX-VP16 B : VAC |
A |
ME |
146 |
58 |
28s |
NS |
|
B |
155 |
60 |
31s |
||||
|
A~B |
144 |
64 |
33s |
||||
|
Maurer, 1985 |
A :MTX-ADR-CPA-CCNU B :CCNU-CPA-VCR C :ADR-VCR |
A |
ML |
157 |
74 |
12m |
NS |
|
B~C |
150 |
72 |
12m |
||||
|
Havemann 1987 |
A :CCNU-ADR-VCR B :VP16-VDS-Ifo C :CPA-MTX-CCNU |
A |
tous |
152 |
59 |
10m |
S |
|
A~B~C |
150 |
70 |
11m |
||||
|
Evans, 1987 |
A : VAC B : CDDP-VP16 |
A |
ME |
144 |
63 |
8m |
S |
|
A~B |
145 |
80 |
10m |
||||
|
Feld, 1987 |
A : VAC B :CDDP-VP16 |
A~B |
ML |
154 |
82 |
62s |
NS |
|
3Aà 3B |
146 |
77 |
60s |
||||
|
Chahinian, 1989 |
A :MTX-ADR-CPA-CCNU B :MMC-VP16-CDDP-HMM |
A |
ME |
86 |
51 |
8m |
NS |
|
A~B |
105 |
48 |
8m |
||||
|
Havemann, 1989 |
A : Ifo-VP16 B :VAC |
A |
tous |
161 |
75 |
10m |
NS |
|
A~B |
165 |
59 |
10m |
||||
|
Goodman, 1990 |
A :VP16-CPA-ADR-VCR B :CDDP-VP16 C :VAC |
A |
ML |
199 |
68 |
15m |
NS |
|
B~C |
201 |
72 |
17m |
||||
|
Ettinger, 1990 |
A :VAC B :HMM-VP16-MTX |
A |
ME |
294 |
61 |
43s |
S |
|
A~B |
283 |
64 |
46s |
||||
|
Fukuoka, 1991 |
A : VAC B :CDDP-VP16 |
A |
tous |
97 |
55 |
10m |
(S) |
|
B |
97 |
78 |
10m |
||||
|
A~B |
94 |
76 |
12m |
||||
|
Wolf, 1991 |
A : Ifo-VP16 B :VAC |
A |
tous |
162 |
77 |
11m |
NS |
|
A~B |
159 |
70 |
10m |
||||
|
Wampler, 1991 |
A : VAC B :MTX-CDDP-VP16 |
A |
ME |
79 |
54 |
7m |
NS |
|
B~A |
82 |
53 |
9m |
||||
|
Roth, 1992 |
A : CDDP-VP16 B : VAC |
A |
ME |
148 |
61 |
9m |
NS |
|
B |
146 |
51 |
8m |
||||
|
A~B |
143 |
60 |
8m |
||||
|
Joss, 1994 |
A :ADR-CDDP-VP16 B :CPA-VP16-ADR C :MTX-VCR-CPA |
A |
tous |
92 |
80 |
319j |
NS |
|
B |
86 |
56 |
265j |
||||
|
C~A |
88 |
88 |
288j |
||||
|
Joss, 1995 |
A :CDDP-ADR-VP16 B :CPA-MTX-VCR-CCNU |
A~B |
tous |
202 |
88 |
339j |
(S) |
|
3Aà 3B |
204 |
87 |
371j |
||||
|
Postmus, 1996 |
A :CPA-ADR-VP16 B :VCR-CBDCA-Ifo |
A |
ME |
75 |
68 |
8m |
NS |
|
A~B |
73 |
70 |
9m |
||||
|
Urban, 1999 |
A :CCNU-CPA-ADR-VP16 B :CCNU-ADR ~CDDP-VDS-VP16 |
A x6 |
tous |
223 |
78 |
306j |
0,08 |
|
B 3x2 |
191 |
64 |
272 j |
Références
(1) Chak LY, Daniels JR, Sikic BI, Torti FM, Lockbaum P, Carter SK. Patterns of failure in small cell carcinoma of the lung. Cancer 1982; 50(9):1857-1863.
(2) Osterlind K, Sorenson S, Hansen HH, Dombernowsky P, Hirsch FR, Hansen M et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 1983; 43(12 Pt 1):6085-6089.
(3) Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK et al. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984; 2(11):1192-1199.
(4) Livingston RB, Mira JG, Chen TT, McGavran M, Costanzi JJ, Samson M. Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1984; 2(6):585-590.
(5) Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol 1985; 3(7):969-976.
(6) Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG et al. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987; 59(6):1072-1082.
(7) Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada [published erratum appears in Ann Intern Med 1988 Mar;108(3):496]. Ann Intern Med 1987; 107(4):451-458.
(8) Feld R, Evans WK, Coy P, Hodson I, MacDonald AS, Osoba D et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987; 5(9):1401-1409.
(9) Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B [see comments]. J Clin Oncol 1989; 7(8):993-1002.
(10) Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R et al. Experience of a German multicenter study group with ifosfamide in small cell lung cancer. Semin Oncol 1989; 16(1 Suppl 3):9-18.
(11) Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol 1990; 8(1):39-47.
(12) Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990; 8(2):230-240.
(13) Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83(12):855-861.
(14) Wolf M, Pritsch M, Drings P, Hans K, Schroeder M, Flechtner H et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients [see comments]. J Clin Oncol 1991; 9(4):614-624.
(15) Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid- Atlantic Oncology Program study. J Clin Oncol 1991; 9(8):1438-1445.
(16) Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10(2):282-291.
(17) Joss RA, Alberto P, Bleher EA, Ludwig C, Siegenthaler P, Martinelli G et al. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5(10):921-928.
(18) Joss RA, Bacchi M, Hurny C, Bernhard J, Cerny T, Martinelli G et al. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995; 6(2):157-166.
(19) Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D et al. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. Eur J Cancer 1996; 32A(9):1498-1503.
(20) Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J et al. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group. Cancer 1999; 86(11):2238-2245.